Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2012 (2012), Article ID 859076, 7 pages
http://dx.doi.org/10.1155/2012/859076
Review Article

Biomarkers for Hepatocellular Carcinoma

1College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA
2Saint Francis Cancer Treatment Center, Grand Island, NE 68803, USA

Received 16 October 2011; Accepted 27 February 2012

Academic Editor: Neil Guha

Copyright © 2012 Tara Behne and M. Sitki Copur. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, F. Bray, and D. M. Pisani, Globocon 2000: Cancer Incidence Mortality and Prevalence Worldwide Version 1.0, no. 5, IARC Press, Lyon, France, 2001.
  2. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA–A Cancer Journal for Clinicians, vol. 55, pp. 74–108, 2005. View at Google Scholar
  3. F. Farinati, D. Marino, M. De Giorgio et al., “Diagnostic and prognostic role of alpha feto protein in hepatocellular carcinoma both or neither?” The American Journal of Gastroenterology, vol. 101, pp. 524–532, 2006. View at Google Scholar
  4. J. C. Trinchet, C. Chaffaut, V. Bourcier et al., “Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3-and 6 month periodicities,” Heaptology, vol. 54, pp. 1987–1997, 2011. View at Google Scholar
  5. D. S. Chen, J. L. Sung, and J. C. Sheu, “Serum α-fetoprotein in the early stage of human hepatocellular carcinoma,” Gastroenterology, vol. 86, no. 6, pp. 1404–1409, 1984. View at Google Scholar · View at Scopus
  6. J. T. Wu, “Serum alpha-fetoprotein and its lectin reactivity in liver diseases: a review,” Annals of Clinical and Laboratory Science, vol. 20, no. 2, pp. 98–105, 1990. View at Google Scholar · View at Scopus
  7. D. S. Chen, J. L. Sung, and J. C. Sheu, “Serum α-fetoprotein in the early stage of human hepatocellular carcinoma,” Gastroenterology, vol. 86, no. 6, pp. 1404–1409, 1984. View at Google Scholar · View at Scopus
  8. V. V. Khien, H. V. Mao, T. T. Chinh et al., “Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma,” International Journal of Biological Markers, vol. 16, no. 2, pp. 105–111, 2001. View at Google Scholar · View at Scopus
  9. M. Capurro, I. R. Wanless, M. Sherman et al., “Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma,” Gastroenterology, vol. 125, no. 1, pp. 89–97, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Nakatsura, Y. Yoshitake, S. Senju et al., “Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker,” Biochemical and Biophysical Research Communications, vol. 306, no. 1, pp. 16–25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Shirakawa, H. Suzuki, M. Shimomura et al., “Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma,” Cancer Science, vol. 100, no. 8, pp. 1403–1407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. B. I. Carr, F. Kanke, M. Wise, and S. Satomura, “Clinical evaluationof lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically provenhepatocellular carcinoma in the United States,” Digestive Diseases and Sciences, vol. 52, pp. 776–782, 2007. View at Google Scholar
  13. R. K. Sterling, L. Jeffers, F. Gordon et al., “Utility of Lens culinaris agglutinin-reactive fraction of alphafetoproteinand des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma,” Clinical Gastroenterology and Hepatology, vol. 7, pp. 104–113, 2009. View at Google Scholar
  14. R. K. Sterling, L. Jeffers, F. Gordon et al., “Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis,” American Journal of Gastroenterology, vol. 102, no. 10, pp. 2196–2205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. I. C. Weitz and H. A. Liebman, “Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review,” Hepatology, vol. 18, no. 4, pp. 990–997, 1993. View at Google Scholar · View at Scopus
  16. J. A. Marrero, G. L. Su, W. Wei et al., “Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients,” Hepatology, vol. 37, no. 5, pp. 1114–1121, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Cui, J. He, F. Zhang et al., “Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein,” British Journal of Cancer, vol. 88, no. 12, pp. 1878–1882, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Tangkijvanich, P. Tosukhowong, P. Bunyongyod et al., “alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 30, no. 1, pp. 110–114, 1999. View at Google Scholar · View at Scopus
  19. P. Tangkijvanich, P. Tosukhowong, P. Bunyongyod et al., “alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 30, no. 1, pp. 110–114, 1999. View at Google Scholar · View at Scopus
  20. S. Liu, L. Ma, W. Huang et al., “Decreased expression of the human carbonyl reductase 2 gene HCR2 in hepatocellular carcinoma,” Cellular and Molecular Biology Letters, vol. 11, no. 2, pp. 230–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Marrero, P. R. Romano, O. Nikolaeva et al., “GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma,” Journal of Hepatology, vol. 43, no. 6, pp. 1007–1012, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. O. Riener, F. Stenner, H. Liewen et al., “Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas,” Hepatology, vol. 49, no. 5, pp. 1602–1609, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Okumoto, E. Hattori, K. Tamura et al., “Possible contribution of circulating transforming growth factor-β1 to immunity and prognosis in unresectable hepatocellular carcinoma,” Liver International, vol. 24, no. 1, pp. 21–28, 2004. View at Google Scholar · View at Scopus
  24. M. Ikeguchi, A. Iwamoto, K. Taniguchi, K. Katano, and Y. Hirooka, “The gene expression level of transforming growth factor-β (TGF-β) as a biological prognostic marker of hepatocellular carcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 24, no. 3, pp. 415–421, 2005. View at Google Scholar · View at Scopus
  25. B. C. Song, Y. H. Chung, J. A. Kim et al., “Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma,” Cancer, vol. 94, no. 1, pp. 175–180, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Zhou, J. Liu, and F. Luo, “Serum tumor markers for detection of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, no. 8, pp. 1175–1181, 2006. View at Google Scholar · View at Scopus
  27. Y. Ito, T. Takeda, M. Sakon et al., “Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma,” British Journal of Cancer, vol. 84, no. 10, pp. 1377–1383, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. W. M. Korn, “Moving toward an understanding of the metastatic process in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 7, no. 6, pp. 777–778, 2001. View at Google Scholar · View at Scopus
  29. S. Osada, M. Kanematsu, H. Imai, and S. Goshima, “Clinical significance of Serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma,” Hepato-Gastroenterology, vol. 55, no. 82-83, pp. 544–549, 2008. View at Google Scholar · View at Scopus
  30. R. T. P. Poon, I. O. L. Ng, C. Lau, W. C. Yu, S. T. Fan, and J. Wong, “Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma,” American Journal of Surgery, vol. 182, no. 3, pp. 298–304, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Safran, K. Charpentier, G. Dubel et al., 2010 Gastrointestinal Cancers Symposium 2010 ASCO abstract.
  32. Y. M. D. Lo and R. W. K. Chiu, “The biology and diagnosticapplications of plasma RNA,” Annals of the New York Academy of Sciences, vol. 1022, pp. 135–139, 2004. View at Google Scholar
  33. A. K. C. Chan, R. W. K. Chiu, and Y. M. D. Lo, “Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis,” Annals of Clinical Biochemistry, vol. 40, no. 2, pp. 122–130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Anker and M. Stroun, “Progress in the knowledge of circulating nucleic acids: plasma RNA is particle-associated. Can it become a general detection marker for a cancer blood test?” Clinical Chemistry, vol. 48, no. 8, pp. 1210–1211, 2002. View at Google Scholar · View at Scopus
  35. M. Matsumura, Y. Niwa, N. Kato et al., “Detection of α-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma,” Hepatology, vol. 20, no. 6, pp. 1418–1425, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. K. S. Jeng, I. S. Sheen, and Y. C. Tsai, “Circulating messenger RNA of α-fetoprotein: a possible risk factor of recurrence after resection of hepatocellular carcinoma,” Archives of Surgery, vol. 139, no. 10, pp. 1055–1060, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Ding, L. Y. Yang, G. W. Huang et al., “Role of AFP mRNA expression in peripheral blood as a predictor for postsurgical recurrence of hepatocellular carcinoma: a systematic review and meta-analysis,” World Journal of Gastroenterology, vol. 11, no. 17, pp. 2656–2661, 2005. View at Google Scholar · View at Scopus
  38. L. Zhou, J. Liu, and F. Luo, “Serum tumor markers for detection of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, no. 8, pp. 1175–1181, 2006. View at Google Scholar · View at Scopus
  39. M. Tsutsumi, D. Sakamuro, A. Takada, S. C. Zang, T. Furukawa, and N. Taniguchi, “Detection of a unique γ-glutamyl transpeptidase messenger RNA species closely related to the development of hepatocellular carcinoma in humans: a new candidate for early diagnosis of hepatocellular carcinoma,” Hepatology, vol. 23, no. 5, pp. 1093–1097, 1996. View at Google Scholar · View at Scopus
  40. I. S. Sheen, K. S. Jeng, and Y. C. Tsai, “Is the expression of gamma-glutamyl transpeptidase messenger RNA an indicator of biological behav- ior in recurrent hepatocellular carcinoma?” World Journal of Gastroenterology, vol. 9, no. 3, pp. 468–473, 2003. View at Google Scholar
  41. T. Himoto, S. Kuriyama, J. Y. Zhang et al., “Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma,” International Journal of Oncology, vol. 27, no. 4, pp. 1079–1085, 2005. View at Google Scholar · View at Scopus
  42. J. F. Tsai, J. E. Jeng, L. Y. Chuang et al., “Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma,” Scandinavian Journal of Gastroenterology, vol. 40, no. 1, pp. 68–75, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. S. T. Cheung, S. T. Fan, Y. T. Lee et al., “Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma,” Transplantation, vol. 85, no. 1, pp. 81–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Ferracin, A. Veronese, and M. Negrini, “Micromarkers: MiRNAs in cancer diagnosis and prognosis,” Expert Review of Molecular Diagnostics, vol. 10, no. 3, pp. 297–308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. http://www.sanger.ac.uk/software/Rfam/mirna/.
  46. A. Budhu, H. L. Jia, M. Forgues et al., “Identification of metastasis-related microRNAs in hepatocellular carcinoma,” Hepatology, vol. 47, no. 3, pp. 897–907, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Yao, L. Liang, S. Huang et al., “Microrna-30d promotes tumor invasion and metastasis by targeting galphai2 in hepatocellular carcinoma,” Hepatology, vol. 51, no. 3, pp. 846–856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. C. C. Wong, C. Wong, E. K. Tung et al., “The MicroRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating rho-kinase 2,” Gastroenterology, vol. 140, no. 1, pp. 322–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Murakami, T. Yasuda, K. Saigo et al., “Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues,” Oncogene, vol. 25, no. 17, pp. 2537–2545, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Coulouarn, V. M. Factor, J. B. Andersen, M. E. Durkin, and S. S. Thorgeirsson, “Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties,” Oncogene, vol. 28, no. 40, pp. 3526–3536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Ladeiro, G. Couchy, C. Balabaud et al., “MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations,” Hepatology, vol. 47, no. 6, pp. 1955–1963, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ura, M. Honda, T. Yamashita et al., “Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma,” Hepatology, vol. 49, no. 4, pp. 1098–1112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. G. E. Chung, J. H. Yoon, S. J. Myung et al., “High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma,” Oncology Reports, vol. 23, no. 1, pp. 113–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Ji, J. Shi, A. Budhu et al., “MicroRNA expression, survival, and response to interferon in liver cancer,” New England Journal of Medicine, vol. 361, no. 15, pp. 1437–1447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Xiong, J. H. Fang, J. P. Yun et al., “Effects of microrna-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma,” Hepatology, vol. 51, no. 3, pp. 836–845, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Zhang, Y. Yang, T. Yang et al., “MicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity,” British Journal of Cancer, vol. 103, no. 8, pp. 1215–1220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Fartoux and T. Decaens, “Contribution of biomarkers and imaging in the management of hepatocellular carcinoma,” Clinics and Research in Hepatology and Gastroenterology, vol. 35, pp. S21–S30, 2011. View at Google Scholar